DRUG
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
Status
Completed
Phase
Phase 2
Enrollment
—
Locations
20
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Jan 22, 2007
Study start
Feb 2006
Primary completion
May 2007
Study completion
May 2007
Results posted
Not reported
Registry updated
Feb 23, 2011
Outcomes
What the study measures.
Primary outcomes
Not reported in the indexed record.
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 21 Years
- Maximum age
- 70 Years
- Sex
- FEMALE
- Healthy volunteers
- Not reported
Inclusion Criteria: * Post menopausal and in general good health * In a stable relationship with a male partner for at least 6 months * Willing to attempt sexual activity once a week with your partner
Study locations
20 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Medical Affiliated Research Center
Huntsville, Alabama, United States
Quality of Life Medical & Research Center, LLC
Tucson, Arizona, United States
University of California, Department of Family and Preventative Medicine
La Jolla, California, United States
Downtown Women's Health Care
Denver, Colorado, United States
Coastal Connecticut Research
New London, Connecticut, United States
South Florida Medical Research
Aventura, Florida, United States
Clinical Study Center
Fort Myers, Florida, United States
Center For Marital and Sexual Health of South Florida
West Palm Beach, Florida, United States
Northeast Indiana Research
Fort Wayne, Indiana, United States
Center for Sexual Medicine at Sheppard Pratt
Baltimore, Maryland, United States
Advanced Biomedical Research, Inc
Hackensack, New Jersey, United States
The Center for Female Sexuality
Purchase, New York, United States
Wake Research Associates, LLC
Raleigh, North Carolina, United States
Lyndhurst Gynecologic Associates
Winston-Salem, North Carolina, United States
The Ohio State University
Columbus, Ohio, United States
Medford Women's Clinic, LLP
Medford, Oregon, United States
Clinical Trials Research Services, LLC
Pittsburgh, Pennsylvania, United States
Advanced Clinical Therapies, Inc.
West Reading, Pennsylvania, United States
Accelovance
Houston, Texas, United States
Women's Clinical Research Center
Seattle, Washington, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Bremelanotide / PT-141.
NCT IDStudyPhase / statusEnrollmentUpdated
Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk
Cosette Pharmaceuticals, Inc. · Lactating Mother
Phase 4
Completed
10
2026-01
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
Palatin Technologies, Inc · Obesity
Phase 2
Active, not recruiting
108
2025-03
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
Kwang Dong Pharmaceutical co., ltd. · Hypoactive Sexual Desire Disorder
Phase 3
Completed
193
2024-11
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
Palatin Technologies, Inc · Kidney Disease
Phase 2
Completed
16
2024-10
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
Imperial College Healthcare NHS Trust · Hypoactive Sexual Desire Disorder
Phase 4
Completed
40
2024-08
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
AMAG Pharmaceuticals, Inc. · Nausea
Phase 1
Completed
228
2022-04
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Palatin Technologies, Inc · Hypoactive Sexual Desire Disorder
Phase 3
Completed
723
2021-04
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Palatin Technologies, Inc · Hypoactive Sexual Desire Disorder
Phase 3
Completed
714
2021-01
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.